Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

Acta Naturae is a peer-reviewed scientific journal published by the Russian Federation Agency for Science & Innovation, focusing on the dynamic fields of Biochemistry, Biotechnology, Molecular Biology, and Molecular Medicine. Launched in 2013, the journal has established a solid reputation in the academic community, with its articles contributing to essential advancements and discussions within these disciplines. By 2023, it has achieved notable rankings—including Q2 status in Biotechnology and Q3 in Biochemistry, Molecular Biology, and Molecular Medicine—indicating its growing influence and relevance in the scientific literature. While currently operating under a non-open access model, Acta Naturae invites researchers, professionals, and students to engage with its comprehensive research reports and reviews that span the breadth of molecular life sciences. With the aim of facilitating scientific dialogue and innovation, this journal serves as a key resource for those seeking to stay at the forefront of molecular research.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.

GROWTH FACTORS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to advancing the field of cell biology, clinical biochemistry, and endocrinology. With an ISSN of 0897-7194 and an E-ISSN of 1029-2292, this journal has served as a vital platform for the dissemination of groundbreaking research since its inception in 1988. Although it operates without an Open Access model, GROWTH FACTORS focuses on providing high-quality, peer-reviewed articles that explore the intricate roles of growth factors in biological processes and their implications in health and disease. Holding a Q4 ranking in Cell Biology and Q3 rankings in Clinical Biochemistry and Endocrinology according to the 2023 category quartiles, the journal is well-regarded in its field and plays a crucial role in informing researchers, professionals, and students alike about the latest findings and innovations in these areas. The journal's commitment to fostering scientific dialogue ensures that it remains a key resource for those looking to enhance their understanding of growth factors and their applications in clinical settings.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.